Shanghai Genomics is on a mission to improve the quality of life throughout the world. We have developed therapeutic products for lung diseases, liver diseases, kidney disease and biomaterials for bone healing. Our drug discovery and development effort focuses on global unmet medical needs.
Our research started from gene target discovery through functional genomics screening of hundreds of enzyme targets. Subsequently, gene functions were identified and validated. Lead compounds were identified through small molecule screening and further validated in at least 3 animal models. Most of the research work was carried out by Shanghai Genomics' in house facility and teams. Shanghai Genomics has also established a network among leading Chinese GLP labs and SFDA designated hospitals for pre-clinical and clinical studies to meet the high standards. After 10 years of research and development, our first New Drug Certificate for a National Class 1.1 drug - Etuary® (F647/pirfenidone) was approved by the CFDA in September, 2011. By the end of December, 2013, our affiliated company, Beijing Continent, had received manufacture permit from CFDA for commercial launch. Etuary® brings new hope to patients of Idiopathic Pulmonary Fibrosis (IPF).
In addition to internal discovery, Shanghai Genomics recognizes the importance of global collaboration in drug development. We have carried out many research programs, ranging from drug target discovery to drug co-development with renowned international pharmas. Shanghai Genomics has adopted flexible business models in these collaborations and proved itself to be a leader in the new drug development ambition of the Chinese pharmaceutical industry.